Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer.

Tsang ES, Spratlin J, Cheung WY, Kim CA, Kong S, Xu Y, Gill S.

Am J Clin Oncol. 2019 Nov 2. doi: 10.1097/COC.0000000000000625. [Epub ahead of print]

PMID:
31693510
2.

Accuracy of Resting Energy Expenditure Predictive Equations in Patients With Cancer.

Purcell SA, Elliott SA, Baracos VE, Chu QSC, Sawyer MB, Mourtzakis M, Easaw JC, Spratlin JL, Siervo M, Prado CM.

Nutr Clin Pract. 2019 Dec;34(6):922-934. doi: 10.1002/ncp.10374. Epub 2019 Jul 25.

PMID:
31347209
3.

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.

Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ.

J Immunother Cancer. 2019 Mar 14;7(1):73. doi: 10.1186/s40425-019-0559-3.

4.

Effect of proximity to specialty care on outcomes for biliary cancers: a population-based retrospective cohort study.

Xu Y, Steckle S, Lui A, Dixon E, Ball CG, Sutherland FR, Spratlin J, Bathe OF.

CMAJ Open. 2019 Feb 28;7(1):E131-E139. doi: 10.9778/cmajo.20180082. Print 2019 Jan-Mar.

5.

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.

Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ.

J Immunother Cancer. 2018 Oct 22;6(1):109. doi: 10.1186/s40425-018-0420-0. Erratum in: J Immunother Cancer. 2019 Mar 14;7(1):73.

6.

A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Lui A, Mulder K, Brezden-Masley C, Vickers M, Monzon J, Kennecke H, Goel R, Vos L, Ghosh S, Marginean H, Fields A, Maroun J, Spratlin J.

Invest New Drugs. 2018 Aug;36(4):674-682. doi: 10.1007/s10637-018-0599-4. Epub 2018 May 4.

PMID:
29725881
7.

Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer.

Loree JM, Sha A, Soleimani M, Kennecke HF, Ho MY, Cheung WY, Mulder KE, Abadi S, Spratlin JL, Gill S.

Clin Colorectal Cancer. 2018 Jun;17(2):156-163. doi: 10.1016/j.clcc.2018.01.010. Epub 2018 Feb 7.

PMID:
29486916
8.

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.

Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, Voss MH, Sharma P, Pal SK, Razak ARA, Kollmannsberger C, Heng DYC, Spratlin J, McHenry MB, Amin A.

J Clin Oncol. 2017 Dec 1;35(34):3851-3858. doi: 10.1200/JCO.2016.72.1985. Epub 2017 Jul 5.

PMID:
28678668
9.

Predictive Impact of Clinical Benefit in Chemotherapy-treated Advanced Pancreatic Cancer Patients in Northern Alberta.

Kim CA, Chu QSC, Fassbender K, Ghosh S, Spratlin JL.

Am J Clin Oncol. 2018 Sep;41(9):867-873. doi: 10.1097/COC.0000000000000385.

PMID:
28368922
10.

Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial.

Chu MP, Hecht JR, Slamon D, Wainberg ZA, Bang YJ, Hoff PM, Sobrero A, Qin S, Afenjar K, Houe V, King K, Koski S, Mulder K, Hiller JP, Scarfe A, Spratlin J, Huang YJ, Khan-Wasti S, Chua N, Sawyer MB.

JAMA Oncol. 2017 Jun 1;3(6):767-773. doi: 10.1001/jamaoncol.2016.3358. Erratum in: JAMA Oncol. 2017 Dec 1;3(12):1742.

11.

Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.

Moore M, Gill S, Asmis T, Berry S, Burkes R, Zbuk K, Alcindor T, Jeyakumar A, Chan T, Rao S, Spratlin J, Tang PA, Rothenstein J, Chan E, Bendell J, Kudrik F, Kauh J, Tang S, Gao L, Kambhampati SR, Nasroulah F, Yang L, Ramdas N, Binder P, Strevel E.

Ann Oncol. 2016 Dec;27(12):2216-2224. doi: 10.1093/annonc/mdw412. Epub 2016 Oct 11.

PMID:
27733377
12.

Concomitant Administration of Proton Pump Inhibitors and Capecitabine is Associated With Increased Recurrence Risk in Early Stage Colorectal Cancer Patients.

Sun J, Ilich AI, Kim CA, Chu MP, Wong GG, Ghosh S, Danilak M, Mulder KE, Spratlin JL, Chambers CR, Sawyer MB.

Clin Colorectal Cancer. 2016 Sep;15(3):257-63. doi: 10.1016/j.clcc.2015.12.008. Epub 2015 Dec 28.

PMID:
26803708
13.

Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.

Kessler ER, Eckhardt SG, Pitts TM, Bradshaw-Pierce EL, O'byrant CL, Messersmith WA, Nallapreddy S, Weekes C, Spratlin J, Lieu CH, Kane MA, Eppers S, Freas E, Leong S.

Invest New Drugs. 2016 Apr;34(2):176-83. doi: 10.1007/s10637-015-0316-5. Epub 2015 Dec 30.

14.

Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer.

Chi KN, Spratlin J, Kollmannsberger C, North S, Pankras C, Gonzalez M, Bernard A, Stieltjes H, Peng L, Jiao J, Acharya M, Kheoh T, Griffin TW, Yu MK, Chien C, Tran NP.

J Clin Pharmacol. 2015 Dec;55(12):1406-14. doi: 10.1002/jcph.564. Epub 2015 Jul 23.

PMID:
26096139
15.

Effects of gender on capecitabine toxicity in colorectal cancer.

Ilich AI, Danilak M, Kim CA, Mulder KE, Spratlin JL, Ghosh S, Chambers CR, Sawyer MB.

J Oncol Pharm Pract. 2016 Jun;22(3):454-60. doi: 10.1177/1078155215587345. Epub 2015 May 22.

PMID:
26002954
16.

A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors.

Chu QS, Sangha R, Spratlin J, Vos LJ, Mackey JR, McEwan AJ, Venner P, Michelakis ED.

Invest New Drugs. 2015 Jun;33(3):603-10. doi: 10.1007/s10637-015-0221-y. Epub 2015 Mar 13.

PMID:
25762000
17.

How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer.

Kim C, Mulder K, Spratlin J.

Oncologist. 2014 Oct;19(10):1046-55. doi: 10.1634/theoncologist.2014-0006. Epub 2014 Aug 20. Review.

18.

Efficacy and safety of single agent or combination adjuvant chemotherapy in elderly patients with colon cancer: a Canadian cancer institute experience.

Kim CA, Spratlin JL, Armstrong DE, Ghosh S, Mulder KE.

Clin Colorectal Cancer. 2014 Sep;13(3):199-206. doi: 10.1016/j.clcc.2014.06.002. Epub 2014 Jun 26.

PMID:
25088184
19.

Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer.

Kim CA, Price-Hiller J, Chu QS, Tankel K, Hennig R, Sawyer MB, Spratlin JL.

Invest New Drugs. 2014 Oct;32(5):1036-45. doi: 10.1007/s10637-014-0113-6. Epub 2014 May 23.

PMID:
24853074
20.

CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer.

Loree JM, Mulder KE, Ghosh S, Spratlin JL.

Clin Colorectal Cancer. 2014 Sep;13(3):172-7. doi: 10.1016/j.clcc.2014.01.001. Epub 2014 Feb 6.

PMID:
24630275
21.

Retrospective comparison of CAPOX and FOLFOX dose intensity, toxicity, and clinical outcomes in the treatment of metastatic colon cancer.

Loree JM, Mulder KE, Ghosh S, Spratlin JL.

J Gastrointest Cancer. 2014 Jun;45(2):154-60. doi: 10.1007/s12029-013-9574-7.

PMID:
24408272
22.

Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.

Wolpin BM, O'Reilly EM, Ko YJ, Blaszkowsky LS, Rarick M, Rocha-Lima CM, Ritch P, Chan E, Spratlin J, Macarulla T, McWhirter E, Pezet D, Lichinitser M, Roman L, Hartford A, Morrison K, Jackson L, Vincent M, Reyno L, Hidalgo M.

Ann Oncol. 2013 Jul;24(7):1792-801. doi: 10.1093/annonc/mdt066. Epub 2013 Feb 28.

23.

First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies.

Yap TA, Arkenau HT, Camidge DR, George S, Serkova NJ, Gwyther SJ, Spratlin JL, Lal R, Spicer J, Desouza NM, Leach MO, Chick J, Poondru S, Boinpally R, Gedrich R, Brock K, Stephens A, Eckhardt SG, Kaye SB, Demetri G, Scurr M.

Clin Cancer Res. 2013 Feb 15;19(4):909-19. doi: 10.1158/1078-0432.CCR-12-2258. Epub 2013 Feb 12.

24.

Clinicopathologic characteristics and survival outcomes of patients with advanced esophageal, gastroesophageal junction, and gastric adenocarcinoma: a single-institution experience.

Dechaphunkul A, Mulder K, El-Gehani F, Ghosh S, Deschenes J, Spratlin J.

Curr Oncol. 2012 Dec;19(6):302-7. doi: 10.3747/co.19.1081.

25.

Impact of a dedicated cancer center surveillance program on guideline adherence for patients with stage II and III colorectal cancer.

Standeven L, Price Hiller J, Mulder K, Zhu G, Ghosh S, Spratlin JL.

Clin Colorectal Cancer. 2013 Jun;12(2):103-12. doi: 10.1016/j.clcc.2012.09.006. Epub 2012 Nov 13.

PMID:
23153862
26.

A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.

Leong S, Eckhardt SG, Chan E, Messersmith WA, Spratlin J, Camidge DR, Diab S, Khosravan R, Lin X, Chow Maneval E, Lockhart AC.

Cancer Chemother Pharmacol. 2012 Jul;70(1):65-74. doi: 10.1007/s00280-012-1880-4. Epub 2012 May 24.

27.

Looking to the future: biomarkers in the management of pancreatic adenocarcinoma.

Spratlin JL, Mulder KE.

Int J Mol Sci. 2011;12(9):5895-907. doi: 10.3390/ijms12095895. Epub 2011 Sep 14. Review.

28.

A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors.

Infante JR, Kurzrock R, Spratlin J, Burris HA, Eckhardt SG, Li J, Wu K, Skolnik JM, Hylander-Gans L, Osmukhina A, Huszar D, Herbst RS.

Cancer Chemother Pharmacol. 2012 Jan;69(1):165-72. doi: 10.1007/s00280-011-1667-z. Epub 2011 Jun 3.

PMID:
21638123
29.

Targeting metastatic upper gastrointestinal adenocarcinomas.

Spratlin JL, Chu Q, Koski S, King K, Mulder K.

World J Clin Oncol. 2011 Mar 10;2(3):135-49. doi: 10.5306/wjco.v2.i3.135.

30.

Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.

Spratlin JL, Pitts TM, Kulikowski GN, Morelli MP, Tentler JJ, Serkova NJ, Eckhardt SG.

Anticancer Res. 2011 Apr;31(4):1093-103.

31.

Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future.

Mulder K, Koski S, Scarfe A, Chu Q, King K, Spratlin J.

Oncotarget. 2010 Nov;1(7):515-29. Review.

32.

The role of bevacizumab in colorectal cancer: understanding its benefits and limitations.

Mulder K, Scarfe A, Chua N, Spratlin J.

Expert Opin Biol Ther. 2011 Mar;11(3):405-13. doi: 10.1517/14712598.2011.557657. Epub 2011 Feb 1. Review.

PMID:
21281258
33.

Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2.

Spratlin J.

Curr Oncol Rep. 2011 Apr;13(2):97-102. doi: 10.1007/s11912-010-0149-5. Review.

PMID:
21222245
34.

Ramucirumab (IMC-1121B): a novel attack on angiogenesis.

Spratlin JL, Mulder KE, Mackey JR.

Future Oncol. 2010 Jul;6(7):1085-94. doi: 10.2217/fon.10.75.

PMID:
20624120
35.

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG.

J Clin Oncol. 2010 Feb 10;28(5):780-7. doi: 10.1200/JCO.2009.23.7537. Epub 2010 Jan 4.

36.

Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions.

Spratlin JL, Mackey JR.

Cancers (Basel). 2010 Dec 2;2(4):2044-54. doi: 10.3390/cancers2042044.

37.

Clinical applications of metabolomics in oncology: a review.

Spratlin JL, Serkova NJ, Eckhardt SG.

Clin Cancer Res. 2009 Jan 15;15(2):431-40. doi: 10.1158/1078-0432.CCR-08-1059. Review.

38.

Community compliance with carcinoembryonic antigen: follow-up of patients with colorectal cancer.

Spratlin JL, Hui D, Hanson J, Butts C, Au HJ.

Clin Colorectal Cancer. 2008 Mar;7(2):118-25. doi: 10.3816/CCC.2008.n.016.

PMID:
18501071
39.

NMR-based metabolomics: translational application and treatment of cancer.

Serkova NJ, Spratlin JL, Eckhardt SG.

Curr Opin Mol Ther. 2007 Dec;9(6):572-85. Review.

PMID:
18041668
40.

Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer.

Jones LW, Eves ND, Mackey JR, Peddle CJ, Haykowsky M, Joy AA, Courneya KS, Tankel K, Spratlin J, Reiman T.

Lung Cancer. 2007 Feb;55(2):225-32. Epub 2006 Nov 17.

PMID:
17113185
41.

Pharmacogenetics of paclitaxel metabolism.

Spratlin J, Sawyer MB.

Crit Rev Oncol Hematol. 2007 Mar;61(3):222-9. Epub 2006 Nov 7. Review.

PMID:
17092739
42.

The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.

Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R, Mackey JR.

Clin Cancer Res. 2004 Oct 15;10(20):6956-61.

43.

Beneficial effects of supplemental buffer and substrate on energy metabolism during small bowel storage.

Salehi P, Spratlin J, Chong TF, Churchill TA.

Cryobiology. 2004 Jun;48(3):245-53.

PMID:
15157773

Supplemental Content

Loading ...
Support Center